Thioacetamide (TAA) is a compound widely used to mimic liver fibrosis. TAA increases the formation of reactive oxygen species (ROS) through its metabolite thioacetamide sulfur dioxide (TASO2), causing severe oxidative stress as well as lipid peroxidation and the generation of protein carbonyl and DNA adducts. Ultimately, TAA induces a progressive liver disease, which is characterized by inflammation, oxidative stress, apoptosis, extensive fibrosis and later development of hepatocellular carcinoma.
Experimental animals: C57BL/6, 6-8-weeks-old, male
Thioacetamide (TAA) administration induced liver fibrosis. 4 and 6 weeks: (A) representative histological images, (B-C) ALT and AST serum levels, (D) positive α-SMA area, and (E) positive sirius red staining area. TAA increased liver fibrosis at both 4 weeks and 6 weeks. Values are expressed as mean ± SEM. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.